nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—UGT2B7—Epirubicin—thyroid cancer	0.214	0.332	CbGbCtD
Dapagliflozin—UGT1A9—Sorafenib—thyroid cancer	0.198	0.307	CbGbCtD
Dapagliflozin—CYP1A2—Sorafenib—thyroid cancer	0.0368	0.057	CbGbCtD
Dapagliflozin—Drug-induced hepatitis—Sorafenib—thyroid cancer	0.0362	0.171	CcSEcCtD
Dapagliflozin—CYP2C9—Sorafenib—thyroid cancer	0.0332	0.0513	CbGbCtD
Dapagliflozin—ABCB1—Sorafenib—thyroid cancer	0.0322	0.0498	CbGbCtD
Dapagliflozin—CYP3A4—Vandetanib—thyroid cancer	0.032	0.0495	CbGbCtD
Dapagliflozin—CYP2D6—Sorafenib—thyroid cancer	0.0303	0.0469	CbGbCtD
Dapagliflozin—Drug-induced liver injury—Sorafenib—thyroid cancer	0.0208	0.0982	CcSEcCtD
Dapagliflozin—ABCB1—Doxorubicin—thyroid cancer	0.0195	0.0302	CbGbCtD
Dapagliflozin—CYP3A4—Sorafenib—thyroid cancer	0.0193	0.0298	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—thyroid cancer	0.0184	0.0285	CbGbCtD
Dapagliflozin—CYP3A4—Doxorubicin—thyroid cancer	0.0117	0.0181	CbGbCtD
Dapagliflozin—Serum creatinine increased—Vandetanib—thyroid cancer	0.00526	0.0248	CcSEcCtD
Dapagliflozin—Balanitis—Epirubicin—thyroid cancer	0.00491	0.0232	CcSEcCtD
Dapagliflozin—Balanitis—Doxorubicin—thyroid cancer	0.00455	0.0215	CcSEcCtD
Dapagliflozin—Fungal infection—Vandetanib—thyroid cancer	0.00419	0.0198	CcSEcCtD
Dapagliflozin—Neoplasm—Vandetanib—thyroid cancer	0.00292	0.0138	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Sorafenib—thyroid cancer	0.00256	0.0121	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Vandetanib—thyroid cancer	0.00241	0.0114	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Epirubicin—thyroid cancer	0.00236	0.0111	CcSEcCtD
Dapagliflozin—Hyponatraemia—Vandetanib—thyroid cancer	0.00236	0.0111	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Vandetanib—thyroid cancer	0.0022	0.0104	CcSEcCtD
Dapagliflozin—Hyperphosphataemia—Doxorubicin—thyroid cancer	0.00218	0.0103	CcSEcCtD
Dapagliflozin—Dehydration—Vandetanib—thyroid cancer	0.00218	0.0103	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Vandetanib—thyroid cancer	0.0021	0.00991	CcSEcCtD
Dapagliflozin—Influenza—Vandetanib—thyroid cancer	0.00203	0.00958	CcSEcCtD
Dapagliflozin—Neoplasm—Sorafenib—thyroid cancer	0.00197	0.00931	CcSEcCtD
Dapagliflozin—Dysuria—Vandetanib—thyroid cancer	0.0019	0.00896	CcSEcCtD
Dapagliflozin—Pollakiuria—Vandetanib—thyroid cancer	0.00187	0.00885	CcSEcCtD
Dapagliflozin—Infestation—Vandetanib—thyroid cancer	0.00181	0.00854	CcSEcCtD
Dapagliflozin—Infestation NOS—Vandetanib—thyroid cancer	0.00181	0.00854	CcSEcCtD
Dapagliflozin—Renal failure—Vandetanib—thyroid cancer	0.00178	0.0084	CcSEcCtD
Dapagliflozin—Urinary tract infection—Vandetanib—thyroid cancer	0.00176	0.0083	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Vandetanib—thyroid cancer	0.0016	0.00757	CcSEcCtD
Dapagliflozin—Urethral disorder—Vandetanib—thyroid cancer	0.00159	0.00752	CcSEcCtD
Dapagliflozin—Hyponatraemia—Sorafenib—thyroid cancer	0.00159	0.00751	CcSEcCtD
Dapagliflozin—Pain in extremity—Sorafenib—thyroid cancer	0.00158	0.00748	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Epirubicin—thyroid cancer	0.00153	0.00724	CcSEcCtD
Dapagliflozin—Venous thrombosis—Epirubicin—thyroid cancer	0.00149	0.00705	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Epirubicin—thyroid cancer	0.00148	0.00696	CcSEcCtD
Dapagliflozin—Dehydration—Sorafenib—thyroid cancer	0.00147	0.00695	CcSEcCtD
Dapagliflozin—Vulvovaginal candidiasis—Doxorubicin—thyroid cancer	0.00142	0.0067	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Sorafenib—thyroid cancer	0.00142	0.00669	CcSEcCtD
Dapagliflozin—Malnutrition—Vandetanib—thyroid cancer	0.00141	0.00668	CcSEcCtD
Dapagliflozin—Venous thrombosis—Doxorubicin—thyroid cancer	0.00138	0.00653	CcSEcCtD
Dapagliflozin—Vulvovaginal mycotic infection—Doxorubicin—thyroid cancer	0.00136	0.00644	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Epirubicin—thyroid cancer	0.00131	0.00619	CcSEcCtD
Dapagliflozin—Hypertension—Vandetanib—thyroid cancer	0.00122	0.00576	CcSEcCtD
Dapagliflozin—Infestation—Sorafenib—thyroid cancer	0.00122	0.00576	CcSEcCtD
Dapagliflozin—Infestation NOS—Sorafenib—thyroid cancer	0.00122	0.00576	CcSEcCtD
Dapagliflozin—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00121	0.00573	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Sorafenib—thyroid cancer	0.0012	0.00568	CcSEcCtD
Dapagliflozin—Renal failure—Sorafenib—thyroid cancer	0.0012	0.00566	CcSEcCtD
Dapagliflozin—Myocardial infarction—Sorafenib—thyroid cancer	0.0012	0.00565	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0012	0.00564	CcSEcCtD
Dapagliflozin—Oedema—Vandetanib—thyroid cancer	0.00115	0.00545	CcSEcCtD
Dapagliflozin—Infection—Vandetanib—thyroid cancer	0.00115	0.00541	CcSEcCtD
Dapagliflozin—Lung disorder—Epirubicin—thyroid cancer	0.00114	0.00538	CcSEcCtD
Dapagliflozin—Skin disorder—Vandetanib—thyroid cancer	0.00112	0.00529	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Sorafenib—thyroid cancer	0.00108	0.00511	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Sorafenib—thyroid cancer	0.00108	0.00508	CcSEcCtD
Dapagliflozin—Urethral disorder—Sorafenib—thyroid cancer	0.00107	0.00507	CcSEcCtD
Dapagliflozin—Lung disorder—Doxorubicin—thyroid cancer	0.00105	0.00498	CcSEcCtD
Dapagliflozin—Fungal infection—Epirubicin—thyroid cancer	0.00104	0.00493	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000996	0.0047	CcSEcCtD
Dapagliflozin—Constipation—Vandetanib—thyroid cancer	0.000987	0.00466	CcSEcCtD
Dapagliflozin—Fungal infection—Doxorubicin—thyroid cancer	0.000966	0.00456	CcSEcCtD
Dapagliflozin—Malnutrition—Sorafenib—thyroid cancer	0.000954	0.0045	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Epirubicin—thyroid cancer	0.000944	0.00446	CcSEcCtD
Dapagliflozin—Extravasation—Epirubicin—thyroid cancer	0.000924	0.00436	CcSEcCtD
Dapagliflozin—Body temperature increased—Vandetanib—thyroid cancer	0.000912	0.00431	CcSEcCtD
Dapagliflozin—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000874	0.00413	CcSEcCtD
Dapagliflozin—Angioedema—Sorafenib—thyroid cancer	0.000872	0.00411	CcSEcCtD
Dapagliflozin—Nocturia—Epirubicin—thyroid cancer	0.000869	0.0041	CcSEcCtD
Dapagliflozin—Extravasation—Doxorubicin—thyroid cancer	0.000855	0.00404	CcSEcCtD
Dapagliflozin—Hypertension—Sorafenib—thyroid cancer	0.000824	0.00389	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000807	0.00381	CcSEcCtD
Dapagliflozin—Nocturia—Doxorubicin—thyroid cancer	0.000804	0.0038	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Sorafenib—thyroid cancer	0.000779	0.00368	CcSEcCtD
Dapagliflozin—Infection—Sorafenib—thyroid cancer	0.000773	0.00365	CcSEcCtD
Dapagliflozin—Dizziness—Vandetanib—thyroid cancer	0.000763	0.0036	CcSEcCtD
Dapagliflozin—Vaginal infection—Epirubicin—thyroid cancer	0.000761	0.00359	CcSEcCtD
Dapagliflozin—Blood urea increased—Epirubicin—thyroid cancer	0.000761	0.00359	CcSEcCtD
Dapagliflozin—Skin disorder—Sorafenib—thyroid cancer	0.000756	0.00357	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—thyroid cancer	0.000729	0.00344	CcSEcCtD
Dapagliflozin—Rash—Vandetanib—thyroid cancer	0.000728	0.00344	CcSEcCtD
Dapagliflozin—Dermatitis—Vandetanib—thyroid cancer	0.000727	0.00343	CcSEcCtD
Dapagliflozin—Headache—Vandetanib—thyroid cancer	0.000723	0.00341	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—thyroid cancer	0.000704	0.00333	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—thyroid cancer	0.000704	0.00333	CcSEcCtD
Dapagliflozin—Nausea—Vandetanib—thyroid cancer	0.000686	0.00324	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—thyroid cancer	0.00068	0.00321	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—thyroid cancer	0.000675	0.00319	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Epirubicin—thyroid cancer	0.000673	0.00318	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000672	0.00317	CcSEcCtD
Dapagliflozin—Constipation—Sorafenib—thyroid cancer	0.000666	0.00314	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—thyroid cancer	0.000629	0.00297	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000623	0.00294	CcSEcCtD
Dapagliflozin—Urticaria—Sorafenib—thyroid cancer	0.000618	0.00292	CcSEcCtD
Dapagliflozin—Body temperature increased—Sorafenib—thyroid cancer	0.000615	0.00291	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—thyroid cancer	0.0006	0.00283	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000597	0.00282	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—thyroid cancer	0.000588	0.00277	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—thyroid cancer	0.000585	0.00276	CcSEcCtD
Dapagliflozin—Hypersensitivity—Sorafenib—thyroid cancer	0.000574	0.00271	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000555	0.00262	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000553	0.00261	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—thyroid cancer	0.000548	0.00259	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—thyroid cancer	0.000544	0.00257	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—thyroid cancer	0.000544	0.00257	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—thyroid cancer	0.000542	0.00256	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000535	0.00252	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—thyroid cancer	0.000523	0.00247	CcSEcCtD
Dapagliflozin—Dizziness—Sorafenib—thyroid cancer	0.000515	0.00243	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000507	0.0024	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—thyroid cancer	0.000506	0.00239	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—thyroid cancer	0.000504	0.00238	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000495	0.00234	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—thyroid cancer	0.000493	0.00233	CcSEcCtD
Dapagliflozin—Rash—Sorafenib—thyroid cancer	0.000491	0.00232	CcSEcCtD
Dapagliflozin—Dermatitis—Sorafenib—thyroid cancer	0.00049	0.00232	CcSEcCtD
Dapagliflozin—Headache—Sorafenib—thyroid cancer	0.000488	0.0023	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000484	0.00229	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—thyroid cancer	0.000473	0.00223	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—thyroid cancer	0.000468	0.00221	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—thyroid cancer	0.000467	0.00221	CcSEcCtD
Dapagliflozin—Nausea—Sorafenib—thyroid cancer	0.000462	0.00218	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—thyroid cancer	0.000456	0.00215	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—thyroid cancer	0.000451	0.00213	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—thyroid cancer	0.000451	0.00213	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—thyroid cancer	0.000443	0.00209	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—thyroid cancer	0.000439	0.00207	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—thyroid cancer	0.000438	0.00207	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—thyroid cancer	0.000432	0.00204	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—thyroid cancer	0.000417	0.00197	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—thyroid cancer	0.000417	0.00197	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—thyroid cancer	0.00041	0.00194	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—thyroid cancer	0.000406	0.00192	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—thyroid cancer	0.0004	0.00189	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—thyroid cancer	0.000398	0.00188	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—thyroid cancer	0.000397	0.00187	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00037	0.00175	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000368	0.00174	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—thyroid cancer	0.000367	0.00173	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—thyroid cancer	0.000353	0.00166	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—thyroid cancer	0.000341	0.00161	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—thyroid cancer	0.000326	0.00154	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—thyroid cancer	0.000316	0.00149	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—thyroid cancer	0.000304	0.00144	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000298	0.00141	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—thyroid cancer	0.000297	0.0014	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—thyroid cancer	0.000288	0.00136	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—thyroid cancer	0.000288	0.00136	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—thyroid cancer	0.000286	0.00135	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—thyroid cancer	0.000282	0.00133	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—thyroid cancer	0.000279	0.00132	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—thyroid cancer	0.000278	0.00131	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000276	0.0013	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—thyroid cancer	0.000274	0.0013	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—thyroid cancer	0.000269	0.00127	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—thyroid cancer	0.000266	0.00126	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000266	0.00126	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—thyroid cancer	0.000264	0.00125	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—thyroid cancer	0.000259	0.00122	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000257	0.00122	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—thyroid cancer	0.000249	0.00117	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000248	0.00117	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—thyroid cancer	0.000246	0.00116	CcSEcCtD
Dapagliflozin—CYP2D6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000235	0.00166	CbGpPWpGaD
Dapagliflozin—UGT1A9—Biological oxidations—RXRA—thyroid cancer	0.000234	0.00165	CbGpPWpGaD
Dapagliflozin—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000233	0.00164	CbGpPWpGaD
Dapagliflozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000232	0.00163	CbGpPWpGaD
Dapagliflozin—UGT1A9—NRF2 pathway—NRG1—thyroid cancer	0.000231	0.00163	CbGpPWpGaD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00023	0.00109	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—thyroid cancer	0.000229	0.00108	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—thyroid cancer	0.000228	0.00107	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—thyroid cancer	0.000227	0.00107	CcSEcCtD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000226	0.00159	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000224	0.00158	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—TPR—thyroid cancer	0.000223	0.00157	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—TPR—thyroid cancer	0.000223	0.00157	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—SLC5A5—thyroid cancer	0.00022	0.00155	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PRKAR1A—thyroid cancer	0.000219	0.00155	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PRKAR1A—thyroid cancer	0.000219	0.00155	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Epirubicin—thyroid cancer	0.000212	0.001	CcSEcCtD
Dapagliflozin—UGT2B7—Metabolism—MINPP1—thyroid cancer	0.000212	0.00149	CbGpPWpGaD
Dapagliflozin—Urticaria—Doxorubicin—thyroid cancer	0.000211	0.000998	CcSEcCtD
Dapagliflozin—UGT1A9—PPARA activates gene expression—PPARG—thyroid cancer	0.000211	0.00149	CbGpPWpGaD
Dapagliflozin—Body temperature increased—Doxorubicin—thyroid cancer	0.00021	0.000994	CcSEcCtD
Dapagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000207	0.00146	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—RXRA—thyroid cancer	0.000206	0.00145	CbGpPWpGaD
Dapagliflozin—CYP2A6—Fluoropyrimidine Activity—TP53—thyroid cancer	0.0002	0.00141	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—CALCA—thyroid cancer	0.000199	0.0014	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CALCA—thyroid cancer	0.000199	0.0014	CbGpPWpGaD
Dapagliflozin—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000199	0.0014	CbGpPWpGaD
Dapagliflozin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000198	0.0014	CbGpPWpGaD
Dapagliflozin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000196	0.000926	CcSEcCtD
Dapagliflozin—CYP1A1—PPARA activates gene expression—RXRA—thyroid cancer	0.000192	0.00136	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000192	0.00135	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NRG1—thyroid cancer	0.000191	0.00135	CbGpPWpGaD
Dapagliflozin—CYP2D6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00019	0.00134	CbGpPWpGaD
Dapagliflozin—Dizziness—Epirubicin—thyroid cancer	0.00019	0.000898	CcSEcCtD
Dapagliflozin—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000189	0.00133	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000188	0.00133	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—RXRA—thyroid cancer	0.000185	0.0013	CbGpPWpGaD
Dapagliflozin—Rash—Epirubicin—thyroid cancer	0.000181	0.000856	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—thyroid cancer	0.000181	0.000856	CcSEcCtD
Dapagliflozin—CYP2A6—Biological oxidations—RXRA—thyroid cancer	0.00018	0.00127	CbGpPWpGaD
Dapagliflozin—Headache—Epirubicin—thyroid cancer	0.00018	0.000851	CcSEcCtD
Dapagliflozin—SLC5A1—Disease—CDK1—thyroid cancer	0.00018	0.00127	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—CDK1—thyroid cancer	0.00018	0.00127	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—NDUFA13—thyroid cancer	0.00018	0.00127	CbGpPWpGaD
Dapagliflozin—CYP1A1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000179	0.00127	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000179	0.00126	CbGpPWpGaD
Dapagliflozin—CYP2A6—NRF2 pathway—NRG1—thyroid cancer	0.000178	0.00125	CbGpPWpGaD
Dapagliflozin—Dizziness—Doxorubicin—thyroid cancer	0.000176	0.000831	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—TPR—thyroid cancer	0.000172	0.00121	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—MINPP1—thyroid cancer	0.000172	0.00121	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.000172	0.00121	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—TERT—thyroid cancer	0.000171	0.00121	CbGpPWpGaD
Dapagliflozin—Nausea—Epirubicin—thyroid cancer	0.000171	0.000807	CcSEcCtD
Dapagliflozin—UGT2B4—Metabolism—PRKAR1A—thyroid cancer	0.000169	0.00119	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—CHST14—thyroid cancer	0.000169	0.00119	CbGpPWpGaD
Dapagliflozin—Rash—Doxorubicin—thyroid cancer	0.000168	0.000792	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—thyroid cancer	0.000168	0.000792	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—thyroid cancer	0.000167	0.000787	CcSEcCtD
Dapagliflozin—SLC5A1—Metabolism—SLC5A5—thyroid cancer	0.000167	0.00118	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—SLC5A5—thyroid cancer	0.000167	0.00118	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HIF1A—thyroid cancer	0.000164	0.00116	CbGpPWpGaD
Dapagliflozin—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000161	0.00114	CbGpPWpGaD
Dapagliflozin—Nausea—Doxorubicin—thyroid cancer	0.000158	0.000747	CcSEcCtD
Dapagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000154	0.00108	CbGpPWpGaD
Dapagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000153	0.00108	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000149	0.00105	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—NDUFA13—thyroid cancer	0.000146	0.00103	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRG1—thyroid cancer	0.000145	0.00102	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRG1—thyroid cancer	0.000145	0.00102	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000143	0.00101	CbGpPWpGaD
Dapagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000143	0.001	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—RXRA—thyroid cancer	0.00014	0.000988	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—RXRA—thyroid cancer	0.00014	0.000988	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—CHST14—thyroid cancer	0.000137	0.000969	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—HPGD—thyroid cancer	0.000136	0.000962	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—BRAF—thyroid cancer	0.000136	0.000957	CbGpPWpGaD
Dapagliflozin—CYP1A1—Biological oxidations—RXRA—thyroid cancer	0.000134	0.000948	CbGpPWpGaD
Dapagliflozin—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000134	0.000944	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—MINPP1—thyroid cancer	0.000133	0.000935	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—TERT—thyroid cancer	0.00013	0.000916	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—TERT—thyroid cancer	0.00013	0.000916	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.00013	0.000914	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—SLC5A5—thyroid cancer	0.000129	0.000908	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000128	0.000906	CbGpPWpGaD
Dapagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000125	0.000878	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HIF1A—thyroid cancer	0.000124	0.000876	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HIF1A—thyroid cancer	0.000124	0.000876	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000122	0.000862	CbGpPWpGaD
Dapagliflozin—CYP1A1—PPARA activates gene expression—PPARG—thyroid cancer	0.000121	0.000856	CbGpPWpGaD
Dapagliflozin—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000119	0.000838	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PPARG—thyroid cancer	0.000117	0.000823	CbGpPWpGaD
Dapagliflozin—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000114	0.000807	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NDUFA13—thyroid cancer	0.000113	0.000795	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—HPGD—thyroid cancer	0.000111	0.000781	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PTGS2—thyroid cancer	0.00011	0.000773	CbGpPWpGaD
Dapagliflozin—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000109	0.00077	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—RXRA—thyroid cancer	0.000108	0.000763	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000107	0.000752	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CHST14—thyroid cancer	0.000106	0.000747	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—BRAF—thyroid cancer	0.000103	0.000725	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—BRAF—thyroid cancer	0.000103	0.000725	CbGpPWpGaD
Dapagliflozin—CYP2D6—Biological oxidations—RXRA—thyroid cancer	0.000101	0.000713	CbGpPWpGaD
Dapagliflozin—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.0001	0.000707	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MINPP1—thyroid cancer	9.88e-05	0.000696	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	9.87e-05	0.000696	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—PTEN—thyroid cancer	9.56e-05	0.000674	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	9.51e-05	0.000671	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PTGS2—thyroid cancer	9.18e-05	0.000647	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	9.11e-05	0.000643	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.99e-05	0.000634	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PPARG—thyroid cancer	8.84e-05	0.000624	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PPARG—thyroid cancer	8.84e-05	0.000624	CbGpPWpGaD
Dapagliflozin—CYP1A2—Biological oxidations—RXRA—thyroid cancer	8.57e-05	0.000604	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—HPGD—thyroid cancer	8.54e-05	0.000602	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—NRAS—thyroid cancer	8.53e-05	0.000601	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NDUFA13—thyroid cancer	8.4e-05	0.000592	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTGS2—thyroid cancer	8.31e-05	0.000586	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTGS2—thyroid cancer	8.31e-05	0.000586	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	8.19e-05	0.000577	CbGpPWpGaD
Dapagliflozin—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	8.19e-05	0.000577	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—PTEN—thyroid cancer	8.01e-05	0.000565	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CHST14—thyroid cancer	7.9e-05	0.000557	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MINPP1—thyroid cancer	7.89e-05	0.000556	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—TPR—thyroid cancer	7.83e-05	0.000552	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	7.71e-05	0.000543	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MINPP1—thyroid cancer	7.43e-05	0.000524	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MINPP1—thyroid cancer	7.37e-05	0.00052	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—KRAS—thyroid cancer	7.34e-05	0.000518	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—PTEN—thyroid cancer	7.25e-05	0.000511	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—PTEN—thyroid cancer	7.25e-05	0.000511	CbGpPWpGaD
Dapagliflozin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	6.96e-05	0.000491	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTGS2—thyroid cancer	6.96e-05	0.000491	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTGS2—thyroid cancer	6.96e-05	0.000491	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PPARG—thyroid cancer	6.83e-05	0.000482	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NDUFA13—thyroid cancer	6.71e-05	0.000473	CbGpPWpGaD
Dapagliflozin—CYP3A4—Biological oxidations—RXRA—thyroid cancer	6.62e-05	0.000466	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—NRAS—thyroid cancer	6.46e-05	0.000456	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—NRAS—thyroid cancer	6.46e-05	0.000456	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—HPGD—thyroid cancer	6.36e-05	0.000449	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—TPR—thyroid cancer	6.36e-05	0.000449	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NDUFA13—thyroid cancer	6.32e-05	0.000446	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CHST14—thyroid cancer	6.31e-05	0.000445	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MINPP1—thyroid cancer	6.3e-05	0.000444	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NDUFA13—thyroid cancer	6.27e-05	0.000442	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PRKAR1A—thyroid cancer	6.26e-05	0.000442	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—HRAS—thyroid cancer	6.24e-05	0.00044	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	6.23e-05	0.00044	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	6.23e-05	0.00044	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.13e-05	0.000432	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—PTEN—thyroid cancer	6.07e-05	0.000428	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—PTEN—thyroid cancer	6.07e-05	0.000428	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CHST14—thyroid cancer	5.94e-05	0.000419	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CHST14—thyroid cancer	5.89e-05	0.000415	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—SLC5A5—thyroid cancer	5.86e-05	0.000413	CbGpPWpGaD
Dapagliflozin—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	5.77e-05	0.000407	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.68e-05	0.0004	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—KRAS—thyroid cancer	5.56e-05	0.000392	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—KRAS—thyroid cancer	5.56e-05	0.000392	CbGpPWpGaD
Dapagliflozin—SLC5A4—Disease—AKT1—thyroid cancer	5.51e-05	0.000389	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTGS2—thyroid cancer	5.37e-05	0.000379	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NDUFA13—thyroid cancer	5.35e-05	0.000378	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.16e-05	0.000364	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—HPGD—thyroid cancer	5.08e-05	0.000358	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CHST14—thyroid cancer	5.03e-05	0.000355	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—RXRA—thyroid cancer	4.93e-05	0.000347	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—TPR—thyroid cancer	4.91e-05	0.000346	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	4.9e-05	0.000346	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MINPP1—thyroid cancer	4.86e-05	0.000343	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	4.83e-05	0.00034	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—HPGD—thyroid cancer	4.79e-05	0.000338	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—SLC5A5—thyroid cancer	4.76e-05	0.000336	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—HPGD—thyroid cancer	4.75e-05	0.000335	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—HRAS—thyroid cancer	4.73e-05	0.000333	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—HRAS—thyroid cancer	4.73e-05	0.000333	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—PTEN—thyroid cancer	4.68e-05	0.00033	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	4.67e-05	0.000329	CbGpPWpGaD
Dapagliflozin—SLC5A4—Metabolism—AKT1—thyroid cancer	4.61e-05	0.000325	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.46e-05	0.000315	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.43e-05	0.000312	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.28e-05	0.000302	CbGpPWpGaD
Dapagliflozin—SLC5A2—Disease—AKT1—thyroid cancer	4.18e-05	0.000294	CbGpPWpGaD
Dapagliflozin—SLC5A1—Disease—AKT1—thyroid cancer	4.18e-05	0.000294	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NDUFA13—thyroid cancer	4.13e-05	0.000291	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGD—thyroid cancer	4.06e-05	0.000286	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—RXRA—thyroid cancer	4e-05	0.000282	CbGpPWpGaD
Dapagliflozin—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.92e-05	0.000276	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.89e-05	0.000275	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CHST14—thyroid cancer	3.89e-05	0.000274	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.85e-05	0.000272	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—SLC5A5—thyroid cancer	3.67e-05	0.000259	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TPR—thyroid cancer	3.66e-05	0.000258	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	3.6e-05	0.000254	CbGpPWpGaD
Dapagliflozin—SLC5A1—Metabolism—AKT1—thyroid cancer	3.5e-05	0.000247	CbGpPWpGaD
Dapagliflozin—SLC5A2—Metabolism—AKT1—thyroid cancer	3.5e-05	0.000247	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.29e-05	0.000232	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.28e-05	0.000232	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.26e-05	0.00023	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGD—thyroid cancer	3.13e-05	0.000221	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PPARG—thyroid cancer	3.11e-05	0.000219	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—RXRA—thyroid cancer	3.09e-05	0.000218	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TPR—thyroid cancer	2.92e-05	0.000206	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.92e-05	0.000206	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PRKAR1A—thyroid cancer	2.87e-05	0.000203	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TPR—thyroid cancer	2.75e-05	0.000194	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—SLC5A5—thyroid cancer	2.74e-05	0.000193	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TPR—thyroid cancer	2.73e-05	0.000192	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	2.71e-05	0.000191	CbGpPWpGaD
Dapagliflozin—UGT2B4—Metabolism—AKT1—thyroid cancer	2.7e-05	0.00019	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.68e-05	0.000189	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.56e-05	0.000181	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PPARG—thyroid cancer	2.53e-05	0.000178	CbGpPWpGaD
Dapagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.47e-05	0.000174	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTGS2—thyroid cancer	2.45e-05	0.000173	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.43e-05	0.000171	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TPR—thyroid cancer	2.33e-05	0.000164	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—RXRA—thyroid cancer	2.3e-05	0.000162	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	2.29e-05	0.000162	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.24e-05	0.000158	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.19e-05	0.000154	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—thyroid cancer	2.13e-05	0.00015	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.08e-05	0.000147	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.06e-05	0.000145	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.04e-05	0.000144	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—thyroid cancer	1.99e-05	0.00014	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PPARG—thyroid cancer	1.95e-05	0.000137	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.91e-05	0.000135	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RXRA—thyroid cancer	1.84e-05	0.000129	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TPR—thyroid cancer	1.8e-05	0.000127	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.77e-05	0.000125	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.74e-05	0.000123	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—thyroid cancer	1.73e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RXRA—thyroid cancer	1.73e-05	0.000122	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RXRA—thyroid cancer	1.72e-05	0.000121	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.67e-05	0.000118	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.63e-05	0.000115	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—thyroid cancer	1.53e-05	0.000108	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RXRA—thyroid cancer	1.47e-05	0.000103	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARG—thyroid cancer	1.45e-05	0.000102	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.43e-05	0.000101	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.35e-05	9.49e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—thyroid cancer	1.34e-05	9.42e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—thyroid cancer	1.23e-05	8.67e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARG—thyroid cancer	1.16e-05	8.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—thyroid cancer	1.14e-05	8.05e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RXRA—thyroid cancer	1.13e-05	7.98e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARG—thyroid cancer	1.09e-05	7.7e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARG—thyroid cancer	1.08e-05	7.64e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—thyroid cancer	9.99e-06	7.05e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—thyroid cancer	9.96e-06	7.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARG—thyroid cancer	9.26e-06	6.53e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—thyroid cancer	9.12e-06	6.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—thyroid cancer	8.59e-06	6.06e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—thyroid cancer	8.52e-06	6.01e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—thyroid cancer	7.95e-06	5.61e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—thyroid cancer	7.7e-06	5.43e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—thyroid cancer	7.5e-06	5.29e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—thyroid cancer	7.43e-06	5.24e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—thyroid cancer	7.28e-06	5.13e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARG—thyroid cancer	7.14e-06	5.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—thyroid cancer	6.35e-06	4.48e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—thyroid cancer	5.74e-06	4.05e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—thyroid cancer	5.62e-06	3.96e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—thyroid cancer	4.9e-06	3.46e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—thyroid cancer	4.58e-06	3.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—thyroid cancer	4.32e-06	3.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—thyroid cancer	4.28e-06	3.02e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—thyroid cancer	3.66e-06	2.58e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—thyroid cancer	2.82e-06	1.99e-05	CbGpPWpGaD
